WO2006062127A1 - 免疫システム異常疾患の診断支援方法及び診断支援情報出力装置 - Google Patents
免疫システム異常疾患の診断支援方法及び診断支援情報出力装置 Download PDFInfo
- Publication number
- WO2006062127A1 WO2006062127A1 PCT/JP2005/022453 JP2005022453W WO2006062127A1 WO 2006062127 A1 WO2006062127 A1 WO 2006062127A1 JP 2005022453 W JP2005022453 W JP 2005022453W WO 2006062127 A1 WO2006062127 A1 WO 2006062127A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- information
- inflammatory
- diagnosis support
- force
- site force
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/55—Specular reflectivity
- G01N21/552—Attenuated total reflection
- G01N21/553—Attenuated total reflection and using surface plasmons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
- G01N29/02—Analysing fluids
- G01N29/022—Fluid sensors based on microsensors, e.g. quartz crystal-microbalance [QCM], surface acoustic wave [SAW] devices, tuning forks, cantilevers, flexural plate wave [FPW] devices
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/025—Change of phase or condition
- G01N2291/0255—(Bio)chemical reactions, e.g. on biosensors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/025—Change of phase or condition
- G01N2291/0256—Adsorption, desorption, surface mass change, e.g. on biosensors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/04—Wave modes and trajectories
- G01N2291/042—Wave modes
- G01N2291/0426—Bulk waves, e.g. quartz crystal microbalance, torsional waves
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Definitions
- the present invention is intended for the treatment of immune system abnormal diseases such as systemic inflammation response syndrome (SIRS) such as sepsis, and anti-inflammation response syndrome (CARS).
- SIRS systemic inflammation response syndrome
- CARS anti-inflammation response syndrome
- Diagnostic support method and diagnostic support information output device for outputting diagnostic support information on symptoms that will appear several hours later by predicting the onset of causal site force-in at the transcriptional stage with respect to the diagnostic support method and diagnostic support information output device Relates to the device.
- Septicemia which is a state in which infection has progressed and presents systemic findings, is initially high fever and hyperventilation, warm blood pressure in the skin is slightly reduced, and tachycardia In the output state, cardiac output is increased and peripheral vascular resistance is decreased. If proper treatment is not performed at this time, respiratory problems such as kidney, liver and blood will progress. There are various treatments such as removal of the source of infection, administration of antibiotics, management of lung kidney and liver, control of DIC, but if appropriate treatment is not performed, various organ disorders (multi-organ failure) develop, You will die. Despite advances in intensive care management, the mortality rate for patients with such severe sepsis is as high as 30-50%.
- SIRS was proposed by Bernard et al. In 1992 and is considered to be abnormal in two or more of the four items reflecting body condition, body temperature, heart rate, respiratory rate, and peripheral blood white blood cell count.
- SI RS is a nonspecific systemic inflammatory reaction triggered by various endogenous mediators regardless of the type of invasion (surgery, severe trauma, burns, infection, etc.), and sepsis ( se p s i s ) In addition, it has non-infectious, non-specific systemic inflammatory response and! / Manic morbidity.
- SIRS treatment is based on experience based on judgment of symptom power. Is being done. Specifically, treatments include large doses of steroids and large doses of anti-inflammatory drugs.
- SIRS symptoms such as hyperthermia and hyperventilation are caused by anti-inflammatory site force-in, not just from a state where the inflammatory reaction caused by inflammatory site force-in is enhanced (hyperimmune state). Similar symptoms are observed even in the anti-inflammatory hypersensitivity state (immunosuppressed state), and if the symptoms are misunderstood, the treatment will be completely reversed. For example, organ dysfunction may develop and death may occur if immunity is reduced due to long-term use of steroids or immunosuppressants.
- Patent Document 1 as a method for identifying and monitoring a patient at risk for a systemic inflammatory condition, a physiological parameter selected by the patient is measured, and the patient's systemic relationship is measured. A method for obtaining a mediator-related response test profile and comparing it to a control profile is proposed. Physiological parameters include physical examination, vital signs, hemodynamic measurements, clinical laboratory tests, acute inflammatory response mediator concentrations, platelet and granulocyte aggregation measurements and endotoxin levels. ing.
- leukotrienes, prostaglandins, cytopower in, platelet activity factor, neutrophil elastase are measured by ELISA, complement component C3a is measured by radioimmunoassay, plasma endotoxin Examples include measuring levels and measuring granulocyte aggregation.
- any physiological parameter, patient force, and blood Measured proteins and growth factors, and the protein to be measured is a secreted product from the cell. Even if it represents the state of the cell at the time of collection, the state at the time of collection is maintained thereafter. It is not always done. In other words, as a cause of difficulty in establishing a method for treating immune system diseases, rapid changes in the pathological condition, that is, site power-in which causes symptoms may change from moment to moment. For this reason, for example, the expression of site force in in the collected sample is measured, and even if significant expression of site force in is recognized, the sample is collected until the force measurement result is obtained. In addition, since the state of expression of site force-in changes, treatment to suppress the measured site force-in is not always appropriate.
- Patent Document 1 JP 10-500210
- the present invention has been made in view of the circumstances as described above, and its purpose is to suggest appropriate diagnosis support information in the treatment of abnormal immune system diseases whose symptoms can change rapidly.
- An object of the present invention is to provide a diagnostic support method for an immune system abnormal disease.
- Another object of the present invention is to provide a diagnosis support information output device capable of outputting appropriate diagnosis support information.
- the diagnosis support method for an immune system abnormal disease of the present invention includes a site force-in selected from the group consisting of inflammatory site force-in and anti-inflammatory site force-inca contained in a biological sample collected from a patient.
- the information on the progress of inflammation includes information on whether or not the inflammatory response is enhanced, and information on whether or not the anti-inflammatory response is enhanced.
- the information group whether or not the expression level of inflammatory site force-in increases and the information force whether or not the expression level of anti-inflammatory site force-in increases Forces may include information on the on-site information selected.
- the diagnosis support information may further include information on a treatment method.
- the treatment method includes: It is preferably selected from the group consisting of administration of an anti-inflammatory agent, plasma exchange and granulocyte colony-stimulating factor.
- the biological sample is preferably a nuclear extract of cells collected by patient force.
- the measurement step is a surface plasmon resonance method preferably performed by a measurement method in which the time until the measurement start force measurement result is obtained is within 1 hour, preferably 30 minutes or less. It is preferable to use one type selected from the group consisting of the quartz resonator microbalance method and the single molecule fluorescence correlation method.
- two or more active transcriptional regulatory factors may be measured.
- the immune system abnormal disease is preferably systemic inflammatory response syndrome (SIRS).
- SIRS systemic inflammatory response syndrome
- the immune system abnormal disease diagnosis support information output device of the present invention is a site force selected from the group consisting of inflammatory site force in and anti-inflammatory site force inca included in a biological sample collected by patient force.
- diagnostic support information output means for outputting diagnostic support information including information on the progress state of the future inflammation.
- the information on the progress of inflammation is selected from a group consisting of information on whether an inflammatory response is enhanced and information on whether an anti-inflammatory response is enhanced. It may contain information, or it may be information on whether or not the expression level of inflammatory site force-in increases and information on whether or not the expression level of anti-inflammatory site force-in increases. Group power may include information on site power in expression selected.
- the diagnosis support information includes information on a treatment method.
- the treatment method is selected from the group consisting of administration of an anti-inflammatory agent, plasma exchange, and granulocyte colony-stimulating factor. Is preferred.
- the diagnosis support information output means stores information on a transcription control factor specific to inflammatory site force-in, transcription control factor information acquired by the information acquisition means, and the storage means. Based on the information, and a prediction means for predicting whether the expression level of inflammatory site force-in increases or not. Based on the prediction result of the prediction means, the diagnostic support information is output. It is preferable to force.
- the storage means may further be a means for storing information on a transcriptional control factor specific to anti-inflammatory site force-in.
- the diagnosis support information output means includes a storage means for storing information on whether or not an inflammatory reaction is enhanced, transcription control factor information acquired by the information acquisition means, and information stored in the storage means.
- the storage means further comprising: a predicting means for predicting power dysfunction that enhances the inflammatory response, and outputting diagnosis support information based on a prediction result of the predicting means. Further, it may be a means for storing information on whether or not the anti-inflammatory reaction is enhanced.
- active transcriptional regulatory factor is a term used to distinguish it from a transcriptional regulatory factor that exists as a complex in the cytoplasm, and is related to the expression of cytoforce-in. A transcriptional regulator that leaves the complex and translocates into the nucleus in order to transcribe the gene.
- diagnostic support method for an immune system abnormal disease of the present invention based on the active transcriptional regulatory factor that controls the transcriptional stage before the development of the site force-in that causes the manifestation of symptoms, It is possible to output diagnostic support information including information on the future progress of inflammation that can occur before the site force in is secreted.
- the diagnosis support information output device of the present invention provides diagnosis support information on the state of inflammation that occurs several hours later based on a sample collected from a patient with an abnormal immune system disease whose symptoms change over time. Output, so that appropriate treatment can be given and precautions can be taken before serious symptoms appear.
- Fig. 1 is an example of a DNA sequence showing a binding site of a transcriptional regulatory factor.
- FIG. 2 is a schematic diagram showing the relationship of transcriptional regulatory factors involved in site force in.
- FIG. 3 is a diagram for explaining the measurement principle of surface plasmon resonance (SPR).
- FIG. 4 is a diagram for explaining the measurement principle of the quartz crystal microbalance method (QCM).
- FIG. 5 is a diagram for explaining the measurement principle of single molecule fluorescence correlation method (FCS).
- FIG. 6 is a diagram for explaining an example of a change in the SIRS state force to the CARS state.
- FIG. 7 is a block diagram showing a hardware configuration of a diagnosis support system for an immune system abnormal disease according to an embodiment of the diagnosis support information output apparatus of the present invention.
- FIG. 8 is a diagram showing a flowchart of an embodiment of a diagnosis support information output process.
- FIG. 9 is a microscopic photograph (400 ⁇ ) showing the result of immunostaining when LiPopolysaccharide is applied to HeLa cells without force.
- FIG. 10 is a photomicrograph (400 ⁇ ) showing the result of immunostaining when lipopolysaccharide was given to HeLa cells.
- FIG. 11 is a photograph showing the result of gel shift assembly.
- FIG. 12 shows the nucleotide probe sequence used in the examples.
- FIG. 13 is a graph showing the measurement results of the presence or absence of HeLa cell binding to a probe.
- FIG. 14 is a photograph showing the result of gel shift assay in which the presence or absence of binding to a probe examined in healthy human lymphocytes was examined.
- FIG. 15 is a graph of SPR measurement results showing the relationship between the concentration of NF ⁇ B and the amount of NF ⁇ -probe complex.
- FIG. 16 is a graph of FCS measurement results showing the relationship between the concentration of NF ⁇ B and the amount of NF ⁇ -probe complex.
- FIG. 17 is a graph of QCM measurement results showing the relationship between the concentration of NF ⁇ B and the amount of NF ⁇ -probe complex.
- FIG. 18 A SPR measurement result diagram showing the relationship between the concentration of SP-1 and the amount of SP-1 probe complex.
- FIG. 19 A SPR measurement result graph showing the relationship between the concentration of AP-1 and the amount of AP-1 probe complex.
- FIG. 20 is a photograph of the expression analysis results (electrophoresis) of IL6 and G-CSF mRNA.
- FIG. 21 is a photograph showing the results of gel shift assay for NF ⁇ B.
- the method for supporting diagnosis of an immune system abnormal disease of the present invention is a biological sample collected from a patient.
- Abnormal diseases of the immune system targeted by the diagnosis support method of the present invention include systemic inflammation anti-J hearts such as sepsis; (Systemic Inflammatory Response Syndrome (S IRS)), anti-inflammatory 3 ⁇ 4E anti-J 3 ⁇ 4E group (Compensatory Anti-inflammatoy response syndrome (CARS)) and the like, and the diagnosis support method of the present invention is particularly suitable for diagnosis support of SIRS.
- systemic inflammation anti-J hearts such as sepsis
- S IRS Systemic Inflammatory Response Syndrome
- CARS Cosmetic Anti-inflammatoy response syndrome
- the biological sample is a sample containing cells collected from patient force, such as patient blood, urine, bronchioloalveolar lavage, saliva, sputum, cerebral bone marrow fluid, joint fluid, infiltrate, etc. .
- the sample to be used for the measurement is preferably a nuclear extract of the cells from which these forces are also collected.
- the active transcriptional regulatory factor to be measured is a transcriptional regulatory factor involved in the transcription of the site force-in to be expressed and is present in the nucleus. It should be noted that since transcriptional regulatory factors usually exist as complexes in the cytoplasm, it is difficult to measure the abundance of transcriptional regulatory factors using a measurement method based on interactions between biomolecules using antibodies or the like.
- the active transcription factor is released from the complex force by a predetermined stimulus. Therefore, the active transcription factor is distinguished from the transcription factor that is not active, and it exists in a measurement method based on the interaction between biomolecules using antibodies. It is possible to measure the quantity.
- the method for preparing the sample containing the nuclear extract is not particularly limited.
- the cells are treated with a hypotonic solution to expand, and the cell membrane is broken using a homogenizer or syringe.
- the nuclear pellet is isolated by centrifugation and treated with a hypertonic solution or a surfactant to extract the nuclear protein, and after centrifugation, the supernatant is recovered. This supernatant contains the protein extracted from the nucleus.
- the active transcription factor to be measured is specific to the Enno-sense sequence that has the function of increasing the expression of the gene encoding target inflammatory site force-in or anti-inflammatory site force-in.
- Transcriptional regulator is It has a DNA binding site (DBD) and a transcription activation site (TAD), and recognizes and binds to a unique sequence.
- DBD DNA binding site
- TAD transcription activation site
- the transcriptional regulator force S bound to the enhancer promotes the transcription initiation complex on the promoter via the S mediator, which stabilizes it.
- Inflammatory site force-in includes, for example, Tumor Necorosis Factor (TNFa), Interleukin 1, Interleukin 2, Interleukin 6, Interleukin 12, Interleukin 18, Platelet Activating Factor (PAF), G— CSF, GM—CSF, and interface.
- TNFa Tumor Necorosis Factor
- Interleukin 1 Interleukin 2
- Interleukin 6 Interleukin 6
- PAF Platelet Activating Factor
- G— CSF CSF
- GM—CSF GM—CSF
- anti-inflammatory site force-in examples include interleukin 4, interleukin 10, interleukin 13, interleukin 1 receptor, soluble TNF receptor, and TGF jS force S.
- site force-ins are controlled at the DNA specific position (DNA specific sequence) at the transcription stage!
- An active transcription regulator binds to a transcriptional regulatory region that regulates the expression of site force-in, particularly an enzyme, RNA polymerase binds to the promoter, transcription is activated, and transcription begins. The generated mRNA is translated to express the encoded site force-in.
- each transcriptional regulatory factor has a fixed DNA sequence. For example, it specifically binds to the sequence shown in Fig. 1. In the figure, a portion surrounded by a square is a coupling region.
- Transcriptional regulators that regulate transcription of site force in vary depending on the type of site force in expressed. Transcriptional regulators usually regulate the expression of one type of site force in cooperation with two or more types of transcriptional regulators. For example, as shown in FIG. 2, transcription factors such as AP-1, CZEBP, and NF KB are involved in interleukin 8 (IL8). In Interguchikin 6 (IL6), AP-1, CREB, C / EBP, and NF KB are involved. In NF2 (IL2), NFAT and AP-1 are involved, and in TNFa, NFKB, ERG1, CRE, AP-1, SP1, and AP-2 are involved.
- IL8 interleukin 8
- IL6 Interguchikin 6
- AP-1, CREB, C / EBP, and NF KB are involved in NF2 (IL2)
- NFAT and AP-1 are involved, and in TNFa, NFKB, ERG1, CRE, AP-1, SP1, and
- TNF ⁇ there are multiple binding sites for NF ⁇ B in the transcriptional regulatory region, and the amount of NF ⁇ B translocated into the nucleus is larger than the site force in (eg IL8, IL6) when there is only one binding site. Conceivable.
- AP-1 and C / EBP are involved in interleukin 4.
- CRE 1, CRE3, CRE 4 are involved in interleukin 10.
- TATA, C / EBP1, C / EBP3, C / EBP5 are involved.
- the active transcription factor to be measured can predict the expression level of inflammatory site force-in or anti-inflammatory site force-in, transcription control common to inflammatory site force-in is sufficient. Only one transcription factor that is not involved in the expression of anti-inflammatory site force in may be measured (when predicting the expression of inflammatory site force in) or common to anti-inflammatory site force in Involved in the expression of inflammatory site force-in with an active transcription factor, only one type of transcription factor may be measured (when predicting the expression of anti-inflammatory site force-in) Alternatively, it may be selected so that the expression of individual site force-in can be predicted from the abundance ratio by measuring the amount of a plurality of types of active transcription factors.
- the site force in particular related to SIRS is IL8, IL6 and TNFa, and the transcriptional control factor common to these is NF ⁇ B.
- IL8 the site force in particular related to SIRS
- IL6 the transcriptional control factor common to these
- NF ⁇ B the transcriptional control factor common to these
- the measurement of the active transcription control factor is preferably performed by a method in which the measurement time until the measurement start force measurement result is obtained is within one hour, more preferably within 30 minutes.
- transcription initiation force is expressed in several hours after the start of transcription force. It is also a force that has been developed, and treatment may be late or wrong.
- Measurement methods with a measurement time of 30 minutes or less include a method for detecting nucleotide hybridization using a nucleotide probe having a specific sequence to which a transcriptional regulatory factor binds, and a method for measuring an interaction between biomolecules. Is preferred. Specific examples include surface plasmon resonance (SPR), quartz crystal microbalance (QCM), single-molecule fluorescence correlation (FCS), and dual polarization interferonmeter-SPR (two-plane polarization interference SPR).
- SPR surface plasmon resonance
- QCM quartz crystal microbalance
- FCS single-molecule fluorescence correlation
- FCS dual polarization interferonmeter-SPR (two-plane polarization interference SPR).
- SPR surface plasmon resonance method
- a metal film thin gold or silver layer laid on the prism surface at a specific angle causes electrons on the metal surface to This is a method that uses the surface plasmon resonance phenomenon caused by the reflected light coming out of the stimulus.
- the surface plasmon resonance and the resonance angle depend on the reflection index, so The presence or absence of chidono and hybrids, that is, the amount of transcriptional regulatory factor bound to the DNA probe can be measured.
- QCM quartz crystal microbalance method
- FCS single-molecule fluorescence correlation method
- a mixture of a measurement sample and a fluorescently labeled nucleotide probe to pass through a confocal region.
- This method utilizes the difference in confocal region transit time due to the difference in size to separate and detect the transcription factor probe complex and the unreacted fluorescent molecule (probe alone) with the number of pulses emitted by one molecule.
- the nucleotide probe used in each of the above methods may be an oligonucleotide probe having a base sequence that specifically binds to a transcription control factor to be detected, and the entire sequence is a wild type that exists in nature. It may be synthesized artificially. Further, only one type of nucleotide probe may be used, or the number of nucleotide probes corresponding to a plurality of transcription control factors involved in the site force-in to be predicted may be provided. Preferably, nucleotide probes corresponding to all transcription control factors are provided! /. This is because by detecting and quantifying multiple transcriptional regulators at once, it is possible to predict the site force-in expression.
- the biomolecular interaction measurement method has a detection sensitivity of ⁇ , and a sample can be quantified in about 10 minutes. Therefore, the patient force can also be collected from the cells and the measurement sample is prepared, and the measurement start can be done within one hour until the measurement result is obtained. You can know the site power in. This predicts whether the symptoms that occur after several hours are anti-inflammatory, inflammatory, and what kind of symptom appears when any site force in appears. It is convenient for In this respect, since ELISA and gel shift assembly take 3 to 6 hours, it is highly possible that the predicted site force-in is likely to be different from the predicted site force-in when the prediction result is obtained. However, there is a problem that it cannot be treated properly. By adopting, it becomes possible to select appropriate treatment and prescription based on prediction.
- diagnosis support information is output.
- diagnosis support information is information on the progress of the future inflammation, and information on whether or not the inflammatory response is enhanced and information on whether or not the anti-inflammatory response is enhanced are selected. It may also contain information, and it also has information about whether or not the amount of expression of inflammatory site force-in increases and information about whether or not the amount of expression of anti-inflammatory site force-in increases.
- the force may also include selected site force in-expression information.
- Measurement force In particular, by using a measurement method in which the time until measurement results are obtained is 30 minutes or less, it is possible to know the site force in developed several hours after taking a patient force sample. Therefore, it is possible to predict whether the symptom that occurs after several hours is an increase in the anti-inflammatory response or an increase in the inflammatory response.
- the diagnosis support information further includes information on a treatment method to be selected, information indicating the suitability of the treatment method (information indicating the suitability of administration of an anti-inflammatory agent, information indicating the suitability of plasma exchange, and granulocyte colony) Information indicating the suitability of administration of the stimulating factor) may be included. Promptness By adopting a certain measurement method, the symptoms that occur after several hours are anti-inflammatory, inflammatory, and what kind of site force-in appears and what symptoms appear Therefore, it is possible to output the selection of appropriate treatment and prescription based on the prediction as diagnostic support information.
- the diagnostic support information output device for an immune system abnormal disease of the present invention is included in a biological sample collected from a patient force, and is specific to a site force in selected from the group consisting of inflammatory site force in and anti-inflammatory site force inca.
- Diagnostic support information output means for outputting support information is provided.
- the transcription factor information may be an abundance of an active transcription factor to be measured, or may be converted into a digital signal obtained by a measuring device that measures the abundance, for example, an abundance. It may be a digital signal corresponding to optical intensity such as fluorescence intensity and reflectance before radiation, radiation intensity, or vibration frequency.
- the information on the progress of inflammation may be information on whether or not an inflammatory reaction is enhanced and information on whether or not an anti-inflammatory reaction is enhanced.
- information on whether or not the increase in the expression level of inflammatory site force-in and information on whether or not the increase in the expression level of anti-inflammatory site force-in is a group force. Selected site force-in expression information Even if it contains.
- diagnosis support information further includes information on the method of treatment in addition to information on the progress of the future inflammation.
- the treatment methods include administration of anti-inflammatory agents, plasma exchange, and granulocytes. It is preferably selected from the group consisting of colony-stimulating factors.
- the diagnosis support information output means is a storage means for storing information on transcription control factors specific to inflammatory site force-in; and transcription control factor information acquired by the information acquisition means and stored in the storage means Does the expression level of inflammatory site force-in increase based on information? It is preferable to include a predicting means for predicting whether or not to output diagnosis support information based on the prediction result of the predicting means.
- the storage means is preferably means for storing information on a transcription control factor specific for anti-inflammatory site force-in.
- the diagnosis support information output means includes a storage means for storing whether or not the inflammatory response is enhanced; and transcription control factor information acquired by the information acquisition means and information stored in the storage means.
- a predicting means for predicting whether or not the expression level of the inflammatory site force in is increased based on the information, and outputting the diagnosis support information based on the prediction result of the predicting means.
- the storage means may be a storage means for storing information as to whether or not the anti-inflammatory reaction is further enhanced.
- diagnosis support information output device of the present invention will be described based on the hardware configuration example of FIG.
- the system 100 including the diagnosis support output device is configured by a computer 100a mainly configured by a main body 110, a display 120, and an input device 130.
- the main body 110 is mainly composed of a CPU lOa, a ROMl lOb, a RAMI 10c, a hard disk 110d, a reading device 110e, an input / output interface 110f, a communication interface 110g, and an image output interface 110h.
- the CPU lOa, the ROM lOb, the RAM 110c, the hard disk 110d, the reading device 110e, the input / output interface 110f, and the image output interface 110h are connected by a bus 110i so that data communication is possible.
- the input / output interface 110f corresponds to the information acquisition unit
- the main body 110 corresponds to the diagnosis support information output unit.
- the storage means specifically corresponds to ROMlOb, RAMI 10c, and hard disk 110d
- the prediction means corresponds to CPUlOa.
- the input / output interface 110f includes, for example, a serial interface such as USB, IEEE1394, RS-232C, a parallel interface such as SCSI, IDE, IEEE1284, and an analog interface that has DZA modification and AZD modification. ing.
- An input device 130 including a keyboard and a mouse is connected to the input / output interface 110f. When the user uses the input device 130, the input device 130 is connected to the computer 100a. Data can be entered.
- the transcription control factor information including the measurement data may be input by the user via the input device 130, and the output unit of the measurement apparatus that measures the abundance of the active transcription control factor and the input / output interface 130 Connect the so that the digital signal obtained by measurement can be directly input as transcription control factor information.
- the CPUlOa serving as the predicting unit can execute the computer program stored in the ROM 110b serving as the storage unit and the computer program loaded in the RAMlOc. Then, the CPU 100a functions as the diagnosis support system 100 when the CPU 110a executes an application program 140a described later. Specifically, it is predicted whether the site force-in expressed based on the information of the active transcriptional regulatory factor input from the information acquisition means is an inflammatory site force-in or an anti-inflammatory site force-in, Based on the prediction result, diagnosis support information is output.
- the information stored in the memory means is information on a transcriptional control factor that causes an increase in the inflammatory response or anti-inflammatory response, whether the inflammatory response is increased or not, the anti-inflammatory response is increased Whether or not, and based on the prediction result, outputs diagnostic support information.
- the storage means is based on the transcription control factor information acquired by the information acquisition means! Information necessary for outputting diagnosis support information, specifically, inflammatory site force-in or anti-inflammatory properties Information on the relationship between the site force-in and the transcriptional regulatory factor, or information on the relationship between the site force-in and the transcriptional regulatory factor that causes an increase in the inflammatory or anti-inflammatory response is stored. Further, the information regarding the treatment method may be stored in at least one of the ROM 110b, the RAM 110c, and the hard disk lOd. Information on the relationship between site force-in and transcriptional regulatory factors includes, for example, information on the type of site force-in expressed in response to transcriptional regulatory factors, and expression of site force-in corresponding to the amount of transcriptional regulatory factors present. Information on amount, expression of transcriptional regulatory factors Time to expression of site force in, etc. are included.
- the ROM 110b is configured by a mask ROM, PROM, EPROM, EEPROM, and the like.
- a computer program executed on the CPUlOa And the data used for this Are recorded.
- the RAMI 10c is configured by SRAM, DRAM, or the like.
- the RAMI 10c is used for reading computer programs recorded in the ROM 110b and the hard disk 110d. Further, when these computer programs are executed, they are used as a work area of the CPU 110a.
- the transcription control factor information input from the input / output interface 110f may be temporarily stored.
- the hard disk 110d includes an operating system that provides a graphical user interface environment such as an operating system (for example, Windows (registered trademark) manufactured and sold by Microsoft Corporation) in addition to information on the relationship between site force-in and transcription control factors. And various computer programs to be executed by the CPU 110a, such as application programs.
- the application program 14 Oa described later is also installed on the hard disk 110d! /.
- the reading device 110e is constituted by a flexible disk drive, a CD-ROM drive, a DV D-ROM drive, or the like, and can read a computer program or data recorded on the portable recording medium 140.
- the portable recording medium 140 stores an abrasion program 140a for causing the computer to function as the diagnosis support system according to the present invention, and the computer 100a relates to the present invention from the portable recording medium 140. It is possible to read the application program 140a and install the application program 140a on the node disk 110d.
- the application program 140a is not only provided by the portable recording medium 140, but also from an external device that is communicably connected to the computer 100a via an electric communication line (whether wired or wireless). It can also be provided through the telecommunications line.
- the application program 140a is stored in the hard disk of a server computer on the Internet.
- the computer 100a accesses the server computer, downloads the computer program, and installs it on the hard disk 110d. Is also possible.
- the image output interface 110h is a display 12 composed of an LCD, a CRT, or the like.
- the video signal corresponding to the image data given from the CPU 110a is output to the display 120.
- the display 120 displays an image (screen) according to the input video signal.
- FIG. 8 showing a flowchart of the SIRS diagnosis support information output process.
- the computer 100a obtains measurement data of active transcription control factors obtained by measuring patient blood (Sl). This measurement data is acquired by inputting the measurement data of the active transcription control factor measured by the measurement device with the input device 130. The sample collection time, the time required for measuring the transcription control factor, and the like are also input by the input device 130. In addition, by connecting the computer 100a and the measuring device via a network such as a LAN, the measurement data of the measuring device force-activated transcription control factor connected to the LAN can be acquired via the input / output interface 110f of the computer 100a. It is possible.
- the CPU 110a predicts the site force-in that will appear based on the acquired measurement data (S2). Prediction of the expression of site force in is performed based on the measured expression level of active NF ⁇ B.
- NF ⁇ B is a transcriptional regulator specific for inflammatory site force-in (IL8, IL6, TNF a) related to SIRS. Therefore, when NF ⁇ B is expressed in a predetermined amount or more, it is possible to predict that inflammatory site force-in of any of IL8, IL6 and TNFa will be expressed after several hours.
- the diagnosis support information corresponding to the prediction of the site force in which it appears is selected and displayed on the display 120 (S3).
- This diagnosis support information includes prediction results as to whether or not the expression level of inflammatory site force-in increases from the time of sample collection, information on the suitability of the treatment method (administration of anti-inflammatory agent), and the like.
- the site force-in expression that is expressed is predicted based on the measurement data of NF ⁇ B.
- the type of transcriptional regulatory factor to be measured is increased, and The type may be predicted.
- APl: C / EBP: NFkB: CREB 1: 1: 1: 1: 1.
- the error in the amount of each transcription factor is about 0.5.
- the HeLa cell culture was centrifuged at 4 ° C and 2000 rpm for 10 minutes, and the collected HeLa cells were washed with 5-: LOml of ice-cold phosphate buffered saline (PBS). (Centrifugation at 4 ° C, 2000 rpm for 10 minutes), buffer A (final concentration: 10 mM HEPES (pH 7.9), 1.5 mM MgCl, lOmM KC1, 0.5 mM DDT) is added to 5-LOLO and suspended. 10 Minute
- swelling of the cell was able to be confirmed by observing with a stereomicroscope. Thereafter, the cells were collected by centrifugation at 4 ° C. and 2000 rpm for 10 minutes, and again suspended in 1 to 5 ml of buffer 1A.
- the cell pulverized product was collected by centrifugation at 15000Xg for 20 minutes at 4 ° C. Buffer C (final concentration: 20mM HEPES (pH7.9), 25vZv% glycerol, 0.42M NaCl, 1.5mM MgCl
- HeLa cultured cells were allowed to react with fluorescently labeled anti-NF ⁇ antibody, and then allowed to stand for 120 minutes, and observed with a fluorescence microscope.
- a photomicrograph (400x magnification) is shown in Fig. 9. When the periphery of the cell nucleus is stained with fluorescent light and is not stimulated, it is encouraging that NF ⁇ is present in the cytoplasm.
- Fig. 10 A photomicrograph (400x magnification) is shown in Fig. 10. The inside of the nucleus is stained with fluorescence, and it can be seen that the administration of lipopolysaccharide translocated NF ⁇ B into the nucleus.
- HeLa cell nuclear extract prepared by the above method (control), Lipopolysaccharide 2.5 mgZml immediately after HeLa cell nuclear extract, Lipopolysaccharide 60 minutes, 120 minutes after nuclear extract, NF ⁇ Gel shift assay was performed using a synthetic oligonucleotide having a B-binding sequence as a probe. The results are shown in FIG.
- a nuclear extract was prepared according to the above-described method of preparing a nuclear extract sample.
- the nuclear extract (0.2 nmol, 1. Onmol) was applied to an SPR device using a metal film implanted with a WT probe and a metal film implanted with a mutation probe, and measurement was performed. As a control, the probe was implanted and the measurement was performed using the nuclear extract on an SPR device using a metal film. The results are shown in FIG.
- the vertical axis represents the Resonance Unit (RU) related to the complex of transcription factor and probe.
- RU Resonance Unit
- Lipopolysaccharide was administered to human lymphocytes of healthy individuals, and a nuclear extract was prepared by the above-described method for preparing a nuclear extract sample.
- Fig. 14 1 is when a nuclear extract is used with a synthetic oligonucleotide probe having an NF ⁇ B binding sequence
- 2 is when a nuclear extract is provided with a mutant probe
- 3 is The case where the nuclear extract was provided using the WT probe is shown.
- the complex of probe and NF ⁇ B appeared strongly in case 3. Therefore, it is apparent that the WT probe is useful as a detection probe for NF ⁇ B even in healthy individuals who are not limited to HeLa cells.
- Sample solution for measurement containing 40 ng, 80 ng, 120 ng, 160 ng, 200 ⁇ g of NF kappa in 20 1 aqueous solution containing lOmM HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA and O.005% Tween20 Prepared.
- the measurement initiation force of NF ⁇ B is within 15 minutes until the measurement result is obtained, and it is possible to know by the time when the cellular force-in expressed after several hours is actually secreted by cellular force It is.
- This sample solution was subjected to NF ⁇ using an SPR device (BIACORE-J, manufactured by Biacore) using a metal film in which a WT probe (5, 1 TGTATCCCCACCCCCTTAAGAA) and a mutation probe (5, -TGTATCCCCAAACCCTTAAGAA) were respectively implanted.
- the measurement was performed in the same manner as in. The results are shown in FIG.
- Sample solution for measurement containing 60 ng, 150 ng, 300 ng, 600 ng of AP-1 in 110 / zl of an aqueous solution containing 10 mM HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA and 0.005% Tween20 Prepared.
- RA rheumatism
- DM EM Dulbecco's modified MEM
- FCS urine fetal serum
- the RA patient-derived fibroblasts (2 ⁇ 10 5 cell / well) in (1) were cultured under low serum (0.5% FCS) conditions for 48 hours before stimulation.
- Thrombin (lOunitZml) was added to this cultured cell solution, and the culture supernatant was collected immediately after addition of thrombin (Otime), 4 hours, 8 hours, 12 hours, and 24 hours later, and secreted by thrombin stimulation.
- the amount of site force in (G—CSF, IL2, IL6) was measured.
- the cyto force in (G—CSF, IL2, IL6) in the culture was measured using the respective ELISA kit (Biosource, Camarillo, Calif.). Table 1 shows the measurement results.
- IL6 is secreted by the thrombin stimulation from cultured fibroblasts in RA patients jointly, and IL-6 has a significant increase in secretion 8 hours after stimulation.
- G-CSF Secretion increased significantly after 12 hours of stimulation.
- IL2 which is known as the same inflammatory site force-in group, did not show a significant increase in secretion due to thrombin stimulation.
- RA patient-derived fibroblasts (2 ⁇ 10 5 cell / well) were cultured under low serum (0.5% FCS) conditions for 48 hours before stimulation.
- thrombin (lOunitZml) to this culture and immediately add thrombin!] 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, Cells were collected every 24 hours and RNA was extracted.
- a reverse transcriptase is added to the obtained RNA sample to synthesize cDNA.
- the PCR product is subjected to agarose gel electrophoresis to obtain the target. mRNA was detected and measured.
- Figure 20 shows the measurement results.
- 8actin is a control rule.
- the primers used in the RT-PCR method are as follows.
- IL6-1 5 '-GCGCCTTCGGTCCAGTTGCCTTGTC
- IL6-2 5 '-CCTCTTTGCTGCTTTCACACATG
- G CSF-1 5 '-AC AGTGC ACTCTGG AC AGT
- G CSF-2 5 '-TCC AGCTGC AGTGTGTCC A
- IL6 mRNA expression was confirmed 4 hours after stimulation in IL6, and G-CSF mRNA expression was confirmed in G-CSF 4-8 hours after stimulation. .
- the RA patient-derived fibroblasts (2 ⁇ 10 5 cell / well) in (1) were cultured under low serum (0.5% FCS) conditions for 48 hours before stimulation. Immediately after thrombin (lOunitZml) was added to this culture solution, the culture fluid cells were collected. The collected cells were washed with PBS, centrifuged, and hypotonic solution (10 mM HEPES / KOH (pH 7.8), 10 mM KC1, 0. ImM EDTA, ImM
- IL6 and G-CSF are active NF ⁇ levels on DNA. It is thought that expression is controlled by the increase in the number of On the other hand, for IL2, which is a site force-in that does not have an NF ⁇ binding sequence on DNA, even if the abundance of active NF ⁇ is increased by thrombin stimulation, an increase in mRNA expression and secretion is observed. I could't.
- diagnosis support method of the present invention information based on the prediction result of the site force-in that appears after several hours can be obtained. It is possible to predict and treat symptoms that occur several hours later for diseases whose symptoms change with time, such as sepsis and SIRS.
- diagnosis support information output device of the present invention in the medical field, it is appropriate to appropriately treat the symptoms that occur after several hours for abnormal immune system diseases that have been difficult to grasp the cause of accurate symptoms. This makes it possible to select an appropriate treatment method, which in turn improves the survival rate and shortens the ICU stay time.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acoustics & Sound (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05814510A EP1835283A4 (en) | 2004-12-10 | 2005-12-07 | METHOD FOR DIAGNOSING DISEASE DISEASE RELATED TO IMMUNE SYSTEM DYSFUNCTION AND INFORMATION OUTPUT DEVICE DIAGNOSTIC SUPPORT |
JP2006546732A JPWO2006062127A1 (ja) | 2004-12-10 | 2005-12-07 | 免疫システム異常疾患の診断支援情報出力装置及び診断支援情報出力プログラム |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004357503 | 2004-12-10 | ||
JP2004-357503 | 2004-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006062127A1 true WO2006062127A1 (ja) | 2006-06-15 |
Family
ID=36577954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/022453 WO2006062127A1 (ja) | 2004-12-10 | 2005-12-07 | 免疫システム異常疾患の診断支援方法及び診断支援情報出力装置 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1835283A4 (ja) |
JP (1) | JPWO2006062127A1 (ja) |
WO (1) | WO2006062127A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009011245A (ja) * | 2007-07-05 | 2009-01-22 | Sysmex Corp | ステロイド感受性の判定方法及び全身性炎症反応症候群の発症予測方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009008608A (ja) | 2007-06-29 | 2009-01-15 | Sysmex Corp | Dna結合タンパクの定量方法及び定量用キット |
CA2788636C (en) * | 2010-03-02 | 2020-07-07 | F. Hoffmann-La Roche Ag | Il-6 detection based early diagnosis and prediction of systemic inflammatory response syndrome and sepsis in asymptomatic patients |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08193854A (ja) * | 1995-01-18 | 1996-07-30 | Terumo Corp | マトリックス電極振動子およびそのセンサ |
JP2002085089A (ja) * | 2000-09-06 | 2002-03-26 | Japan Science & Technology Corp | 細胞活性の評価方法 |
JP2002543414A (ja) * | 1999-04-29 | 2002-12-17 | エボテック オーアーイー アクチェンゲゼルシャフト | 生成関数を用いて蛍光分子又は他の粒子を特徴付ける方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1270740A1 (en) * | 2001-06-29 | 2003-01-02 | SIRS-Lab GmbH | Biochip and its use for determining inflammation |
US20030162190A1 (en) * | 2001-11-15 | 2003-08-28 | Gorenstein David G. | Phosphoromonothioate and phosphorodithioate oligonucleotide aptamer chip for functional proteomics |
-
2005
- 2005-12-07 EP EP05814510A patent/EP1835283A4/en not_active Withdrawn
- 2005-12-07 JP JP2006546732A patent/JPWO2006062127A1/ja active Pending
- 2005-12-07 WO PCT/JP2005/022453 patent/WO2006062127A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08193854A (ja) * | 1995-01-18 | 1996-07-30 | Terumo Corp | マトリックス電極振動子およびそのセンサ |
JP2002543414A (ja) * | 1999-04-29 | 2002-12-17 | エボテック オーアーイー アクチェンゲゼルシャフト | 生成関数を用いて蛍光分子又は他の粒子を特徴付ける方法 |
JP2002085089A (ja) * | 2000-09-06 | 2002-03-26 | Japan Science & Technology Corp | 細胞活性の評価方法 |
Non-Patent Citations (3)
Title |
---|
PENNER G. ET AL: "C/EBP DNA-binding activity is upregulated by a glucocorticoid-dependent mechanism in septic muscle", AM J PHYSIOL REGLATORY INTEGRATIVE COMP PHYSIOL., vol. 282, 2002, pages R439 - R444, XP002995235 * |
See also references of EP1835283A4 * |
YANG R.-C. ET AL: "Potential protective effect of NF-kappaB activity on the polymicrobial sepsis of rats preconditioning heat shock treatment", CLINICA CHIMICA ACTA, vol. 302, 2000, pages 11 - 22, XP002995236 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009011245A (ja) * | 2007-07-05 | 2009-01-22 | Sysmex Corp | ステロイド感受性の判定方法及び全身性炎症反応症候群の発症予測方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1835283A4 (en) | 2008-05-07 |
JPWO2006062127A1 (ja) | 2008-06-12 |
EP1835283A1 (en) | 2007-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4250765B2 (ja) | 冠状動脈疾患の予測 | |
Reed et al. | Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history | |
US10196690B2 (en) | Biomarkers for the diagnosis of lacunar stroke | |
Díaz-Jiménez et al. | Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution | |
KR102054857B1 (ko) | 질환의 진단용 조성물 | |
JP2006014740A (ja) | 血管移植片疾患の管理と治療のシステム及び方法 | |
Mariani et al. | Serum calprotectin: review of its usefulness and validity in paediatric rheumatic diseases | |
Manichaikul et al. | Plasma soluble receptor for advanced glycation end products in idiopathic pulmonary fibrosis | |
JP2022512664A (ja) | 骨髄幹細胞治療に対する応答の予測方法 | |
Ruffner et al. | Conserved IFN signature between adult and pediatric eosinophilic esophagitis | |
WO2006062127A1 (ja) | 免疫システム異常疾患の診断支援方法及び診断支援情報出力装置 | |
de Jong et al. | Synovial gene signatures associated with the development of rheumatoid arthritis in at risk individuals: A prospective study | |
Zhu et al. | Hsa_circ_0000437 upregulates and promotes disease progression in rheumatic valvular heart disease | |
CN108913769A (zh) | 早期诊断心肌梗死的分子标志物 | |
Lindsey et al. | Identifying the molecular and cellular signature of cardiac dilation following myocardial infarction | |
Gueye et al. | Biomarkers for Endometriosis in saliva, urine, and peritoneal fluid | |
Tofigh et al. | Serum Levels of Long Non-coding RNAs NEAT1, GAS5, and GAPLINC Altered in Rheumatoid Arthritis | |
JP2004505648A5 (ja) | ||
Kraaijenhof et al. | Plasma C-reactive protein is associated with a pro-inflammatory and adverse plaque phenotype | |
JP5676777B2 (ja) | 関節リウマチ活動性指標を同定する方法及びそれに用いるバイオマーカー | |
CN114134226B (zh) | 心绞痛相关的标志物及其应用 | |
US20230332236A1 (en) | Method for diagnosing stroke utilizing gene expression signatures | |
Sakr et al. | Long noncoding RNA as a diagnostic tool in vascular complication of diabetes | |
JP2023540426A (ja) | 前立腺癌診断スコアを算出するための方法及びそれの使用 | |
TWI695889B (zh) | 評估抗生素磺胺甲噁唑及/或甲氧苄啶引發藥物過敏反應風險的方法、其檢測試劑及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006546732 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005814510 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005814510 Country of ref document: EP |